Rusfertide not checked
Protagonist Therapeutics, Inc. · TAK-121 · PTG-300
FollowEvery change as it happens, and a Monday email
Trials
4 active
10 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Polycythemia Vera (4 trials)
- Main trialPhase 3
- “Polycythemia vera (PV) is a long-term condition in which the bone marrow makes too many red blood cells (RBCs). Bone marrow is the soft tissue inside the large bones where blood cells are made. When there are too many RBCs, called erythrocytosis, the blood can become thicker and move less easily through blood vessels and organs. This can raise the risk of blood clots (thrombosis) in veins or arteries. Sometimes, these clots can be life-threatening and may cause a stroke or heart attack. Treatment aims to keep the percentage of RBCs in the blood (hematocrit) in a safe range. For adults with…”In the company’s words, NCT05210790 on ClinicalTrials.gov
- Other names
- TAK-121 · PTG-300
Other drugs for Polycythemia Vera
- Givinostat HydrochlorideItalfarmaco · Phase 3
- AG-236Agios Pharmaceuticals, Inc. · Phase 2/3
- BomedemstatMerck & Co. · Phase 3
- Ropeginterferon alfa-2bPharmaEssentia · Phase 3
- FlonoltinibChengdu Zenitar Biomedical Technology Co., Ltd · Phase 2
- DISC-3405Disc Medicine, Inc · Phase 2
Coming up2
- 28 Oct 2027Phase 2 trial completes · ClinicalTrials.gov
- 1 Jul 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 21 Feb 2025 | A Study of Rusfertide in Adults With Polycythemia Vera (PV) | |
| Phase 3Active, not recruiting | 1 Apr 2026 | Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera | |
| Phase 2Recruiting | 28 Oct 2027 | A Study of Rusfertide in Japanese Adults With Polycythemia Vera | |
| Phase 2Not yet recruiting | 1 Jul 2028 | A Study of Rusfertide in Adults With Polycythemia Vera in China | |
| Phase 2Completed | 31 Jul 2020 | Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia | |
| Phase 2Completed | 31 Jul 2020 | Safety Study for Beta Thalassemia Subjects on PTG-300 | |
| Phase 2Completed | 6 Oct 2021 | PTG-300 in Subjects With Hereditary Hemochromatosis | |
| Phase 2Completed | 14 Feb 2023 | Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) | |
| Phase 2Completed | 15 Mar 2023 | PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit | |
| Phase 1Completed | 12 Jan 2021 | Pharmacokinetics and Pharmacodynamics of Different PTG-300 Regimens in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026